CFM
VRDN icon

Catalyst Funds Management’s Viridian Therapeutics VRDN Stock Holding History

Catalyst Funds Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,900
Closed -$43.2K – 1256
2024
Q3 		$43.2K Sell
1,900
-3,100
-62% -$50.7K 0.01% 854
2024
Q2 		$65K Buy
5,000
+2,300
+85% +$31.8K 0.02% 369
2024
Q1 		$47.3K Buy
+2,700
New +$52.3K 0.01% 574

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Catalyst Funds Management's VRDN Position: Q4 2024 in Review

Catalyst Funds Management sold out of Viridian Therapeutics (VRDN) in Q4 2024, closing a stake of 1,900 shares — an estimated $43.2K sold.

Catalyst Funds Management first reported a position in VRDN in Q1 2024 and held it in 3 quarters. The position peaked at $65K in Q2 2024. 178 funds tracked by Wall St. Rank hold VRDN as of Q4 2024.

  • Catalyst Funds Management reported no remaining Viridian Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 1,900 Viridian Therapeutics shares in Q4 2024, an estimated $43.2K.
  • Catalyst Funds Management first reported a position in Viridian Therapeutics in Q1 2024 and held it in 3 quarters.
  • Catalyst Funds Management's Viridian Therapeutics position peaked at $65K in Q2 2024.
  • 178 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2024.

Based on Catalyst Funds Management's 13F filing for Q4 2024, filed 10 Feb 2025.